TABLE 2.
Response and progression‐free survival outcomes to Bruton tyrosine kinase inhibitors in patients with Waldenström macroglobulinemia according to CXCR4 mutational status
| Study (Setting) | Regimen | CXCR4 mutational status | Time to major response | PR or better | VGPR or better | PFS |
|---|---|---|---|---|---|---|
| Treon et al. 15 (RR) | Ibrutinib | Wild type | 4.7 months | 97% | 47% | 70% at 5 years |
| Mutated | 1.8 months | 68% | 9% | 38% at 5 years | ||
| Trotman et al. 17 (RR) | Ibrutinib | Wild type | NA | 88% | 41% | NR at 5 years |
| Mutated | NA | 71% | 14% | Median: 18 months | ||
| Castillo et al. 19 (TN) | Ibrutinib | Wild type | 7.3 months | 94% | 44% | 90% at 4 years |
| Mutated | 1.8 months | 78% | 14% | 59% at 4 years | ||
| Buske et al. 21 (TN, RR) | Ibrutinib plus rituximab | Wild type | 3 months | 81% | 44% | 72% at 4.5 years |
| Mutated | 2 months | 77% | 23% | 63% at 4.5 years | ||
| Tam et al. 29 (TN, RR) | Ibrutinib | Wild type | NA | 82% | 24% | NA |
| Mutated | NA | 65% | 10% | NA | ||
| Zanubrutinib | Wild type | NA | 82% | 34% | NA | |
| Mutated | NA | 70% | 18% | NA |
Abbreviations: N/A, not available; NR, not reached; PFS, progression‐free survival; PR, partial response; RR, relapsed or refractory; TN, treatment naïve; VGPR, very good partial response.